Arcturus Therapeutics

Arcturus Therapeutics Holdings, Inc. develops pharmaceuticals. It is a clinical-stage mRNA medicines and vaccines company, which focuses on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. The firm's products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Arcturus Therapeutics Reports Strong Q1 Earnings and Advances COVID-19 Vaccine

Arcturus Therapeutics delivered strong financial results in Q1 2023, driven by the promising performance of its COVID-19 vaccine candidate, ARCT-154. The company faces challenges related to undisclosed rights and economic benefits, along with the need for longer safety studies. However, it has opportunities to expand its mRNA therapeutic candidates and leverage its LUNAR technology for future growth.

Arcturus Therapeutics reports strong Q2 earnings and outlines expansion plans

Arcturus Therapeutics showcased strong financial performance and promising developments in its pipeline, particularly with the ARCT-154 COVID-19 vaccine Phase 3 program. While facing challenges related to approval timing, manufacturing capacity, and data reporting, the company is well-positioned to capitalize on opportunities for expansion and commercialization.

Arcturus reports Q3 revenues of $45.1M, ARCT-154 vaccine progress

Arcturus Therapeutics reported mixed financial performance for Q3 2023, with strong progress in COVID-19 vaccine development and ongoing studies for mRNA therapeutic candidates. The company faces recruitment and commercialization challenges but sees opportunities in market potential and mRNA vaccine technology. Overall, Arcturus remains focused on advancing its pipeline and addressing key industry challenges.

Arcturus Therapeutics reports solid earnings, eyes Japan's vaccine market

Arcturus Therapeutics showcased strong revenue generation, ongoing vaccine development, and a focus on safety and efficacy. Challenges include high operating expenses and the need to address analyst concerns about financial impacts and distribution. Opportunities lie in the potential of the Kostaive market and expansion into new vaccine programs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings, Inc. (ARCT) CEO Joseph Payne on Q4 2019 Results - Earnings Call Transcript

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -55.10% and -34.04%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Arcturus Therapeutics (ARCT) Reports Q4 Loss, Lags Revenue Estimates

Arcturus Therapeutics (ARCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Arcturus Therapeutics (ARCT) Expected to Beat Earnings Estimates: Should You Buy?

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) stock jumped on Wednesday after the company announced that it would be joining the fight against the latest coronavirus.

What Arcturus Therapeutics Brings to the Fight Against the Coronavirus

Collaboration seeks to conduct pre-clinical testing followed by first-in-human clinical trials Collaboration seeks to conduct pre-clinical testing followed by first-in-human clinical trials

Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR Technology™

SAN DIEGO, Jan.  08, 2020  (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced the appointment of Steve Hughes, M.D., as Chief Development Officer, effective January 2, 2020. Dr. Hughes brings over twenty years of clinical development experience in the fields of rare diseases, cardiovascular disease, and oncology. His most recent successes include RNA therapeutic approvals at Ionis Pharmaceuticals for the treatment of rare diseases including transthyretin-mediated amyloidosis (TEGSEDI®), familial chylomicronemia syndrome (WAYLIVRA®) and spinal muscular atrophy (SPINRAZA®).  

Arcturus Therapeutics Appoints Steve Hughes, M.D., as Chief Development Officer

SAN DIEGO, Nov.  07, 2019  (GLOBE NEWSWIRE) -- Arcturus Therapeutics (NASDAQ: ARCT, the “Company”), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that the Company is expanding its platform to include STARR (Self-Transcribing And Replicating RNA) technology™ for human and animal health vaccine applications.

Arcturus Therapeutics Expands Platform with STARR Technology™

Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Arcturus Therapeutics (ARCT) Report Negative Q3 Earnings? What You Should Know

Arcturus Therapeutics (ARCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Arcturus Therapeutics (ARCT) Upgraded to Buy: Here's What You Should Know

SAN DIEGO, Oct.  02, 2019  (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (“Arcturus Therapeutics”) (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that Joseph Payne, Chief Executive Officer, will provide a corporate overview at three upcoming investor conferences: the Chardan Capital Markets 3rd Annual Genetic Medicines Conference, October 7-8 in New York City; the Stifel Healthcare Conference 2019, November 19-20 in New York City; and, the LD Micro Annual Main Event, December 10-12th in Bel Aire, California.

Arcturus Therapeutics to Present at Three Upcoming Investor Conferences

SAN DIEGO, Sept.  23, 2019  (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (“Arcturus Therapeutics”) (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that Professor Edward W. Holmes, M.D., joined the Board of Directors and Andy Sassine was re-appointed effective September 17, 2019.  

Arcturus Therapeutics Announces Appointment of Dr. Edward Holmes M.D.

President and CEO of Arcturus Therapeutics Holdings Inc (30-Year Financial, Insider Trades) Joseph E Payne (insider trades) bought 5,000 shares of ARCT on 08/29/2019 at an average price of $11.22 a share.

Arcturus Therapeutics Holdings Inc (ARCT) President and CEO Joseph E Payne Bought $56,100 of Shares

SAN DIEGO, Aug.  26, 2019  (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (“Arcturus Therapeutics”) (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that Joseph Payne, Chief Executive Officer, will present a corporate update at the H.C. Wainwright 21st Annual Global Investment Conference, and the Ladenburg Thalmann 2019 Healthcare Conference.

Arcturus Therapeutics To Present at Two Investor Conferences in September

CFO of Arcturus Therapeutics Holdings Inc (30-Year Financial, Insider Trades) Andy Sassine (insider trades) bought 10,000 shares of ARCT on 08/23/2019 at an average price of $10.9 a share.

Arcturus Therapeutics Holdings Inc (ARCT) CFO Andy Sassine Bought $109,000 of Shares

Arcturus Therapeutics (ARCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

What Makes Arcturus Therapeutics (ARCT) a New Strong Buy Stock

Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q2 2019 Results - Earnings Call Transcript

CACI

Barrick Gold

JD.com

Victory Capital Holdings

In line with better-than-expected earnings reports, five companies are set to beat earnings estimates next week.

5 High-Flying Stocks Set to Beat on Earnings in Q2 Next Week

The FDA grants orphan drug designation to Arcturus Therapeutics' (ARCT) candidate, ARCT-810 for treating patients with ornithine transcarbamylase deficiency, the most common urea cycle disorder.

Arcturus Metabolic Disorder Candidate Gets Orphan Drug Status

Ultragenyx Pharmaceutical

Ultragenyx (RARE) and Arcturus Therapeutics expand their existing collaboration to discover and develop mRNA, DNA and siRNA therapeutics for up to 12 rare disease targets.

News for Arcturus Therapeutics Stock (ARCT)